Skip to main content

Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting


While important advances have been made in the prevention and treatment of Human Immunodeficiency Virus (HIV) infection, limited expertise and resource constraints to effectively manage rollout of HIV programs often contribute to poor treatment outcomes in Sub-Saharan Africa. In 1998, the University of Zimbabwe (UZ) and the University at Buffalo, State University of New York (UB), developed a collaborative clinical pharmacology capacity building program in Zimbabwe to train the next generation of HIV researchers and support rollout of the national HIV program. The collaboration was funded by research and training grants that were competitively acquired through United States of America government funding mechanisms, between 1998 and 2016. Thirty-eight research fellows were trained and a specialty clinical pharmacology laboratory was established during this period. Knowledge and skills transfer were achieved through faculty and student exchange visits. Scientific dissemination output included sixty-two scholarly publications that influenced three national policies and provided development of guidelines for strategic leadership for an HIV infection—patient adherence support group. The clinical pharmacology capacity building program trained fellows that were subsequently incorporated into the national technical working group at the Ministry of Health and Child Care, who are responsible for optimizing HIV treatment guidelines in Zimbabwe. Despite serious economic challenges, consistent collaboration between UZ and UB strengthened UZ faculty scholarly capacity, retention of HIV clinical research workforce was achieved, and the program made additional contributions toward optimization of antiretroviral therapy in Zimbabwe.


The use of potent combination antiretroviral therapy (cART) has led to successful treatment of HIV infection in most high-income countries [1]. However, treatment outcomes are often poor in sub-Saharan African countries for a variety of reasons, complicating the ability of individual countries to achieve the United Nations 95-95-95 target. The factors that contribute to these variable outcomes are diverse, but they indicate the need for building a team of researchers who are able to investigate the key clinical and implementation research questions related to optimizing HIV-1 prevention and treatment in Zimbabwe and other African countries. Challenges with financing of programs, poor health systems, suboptimal patient adherence and shortage of healthcare workers have been cited in many low to middle income countries (LMIC) [2]. Ideally, governments should commit to funding national antiretroviral programs in order to strengthen health systems, develop infrastructure and retain healthcare workers. Other capacity development projects modelled around north–south collaborations such as the African/Asian Regional Capacity Development (ARCADE) have also been useful in strengthening health systems in developing countries [3].

Retention of healthcare workers, particularly professionals with a specialist understanding of HIV and ART management is important to facilitate evidence-based optimization of ART [4]. Broadening the number of individuals who contribute to HIV care may be of value, including alternative primary care models that identify additional health providers (e.g., physician assistants, nurse practitioners, clinical pharmacists). Innovative models that integrate social and behavioural health aspects of HIV infection management have been developed. These maximize the use of a team approach to address the challenges that arise in the management of complex patients and encourage health provider led patient support groups.

In Zimbabwe, shortage of healthcare professionals has hampered the national response to the HIV epidemic, among other factors like inadequate access to health care, severe foreign currency shortages, hyperinflation, and limited industrial capacity [5,6,7]. The initial shortage of healthcare professionals was fuelled by brain drain as qualified personnel left the country to practice in more viable economies [8]. This in turn reduced the capacity for academic and healthcare institutions to train healthcare professionals [9, 10]. In this regard, the University of Zimbabwe (UZ) and the University at Buffalo State University of New York (UB), developed a collaborative HIV Clinical Pharmacology capacity building program whose aim was to train the next generation of HIV researchers, initially to support rollout of the national HIV program followed later by clinical and translational pharmacology research. It was conceptualised that by engaging multi-disciplinary researchers and various approaches such as fellowship programs, outcomes such as mentors for further translational training could be realised. The program would leverage on building capacity in HIV research whilst strengthening positive HIV treatment outcomes in the process. Training programs comprised of multidisciplinary fellows who would through the course of training have a strong thrust towards patient monitoring and retention. As far as can be ascertained, this is the only program that incorporated continued engagement with patients and research participants to ensure that patients who are ultimate beneficiaries of the research process would be active contributors to the research process.

This review article describes the implementation process, major achievements, challenges and the future direction of the collaboration.

Description and implementation of the collaboration

Description of the collaboration

The collaborative relationship between UZ and UB started in 1998, following the recommendation by the International AIDS Society (IAS) in 1997 to roll out cART. cART was identified to be the optimal treatment modality for people living with HIV even though the feasibility of providing cART in developing countries was fraught with logistical doubts [9]. One component of this collaboration was initiated to respond to the demand for cART rollout in Zimbabwe. The collaboration was subsequently formalized and managed through a memorandum of understanding (MOU) signed between UZ and UB in 2002. The MOU between UZ and UB was renewed three times between 2002 and 2017.

Based on the combined experiences and knowledge of international collaborations, the ‘bridge-building’ framework was developed (Table 1). The framework asserts the importance of building a bridge to facilitate the transfer of technological and human skills resources between highly resourced and lowly resource setting. The ‘bridge-building’ is based upon the input-process-outcomes framework. This framework was used as the analytical lens to explore the collaborative capacity building and knowledge transfer program.

Table 1 Bridge Building framework for the UZ and UB collaboration between 1998 and 2018

Implementation of the collaboration

Faculty and students from both the UZ and UB took part in exchange visits (Fig. 1). Students studying at masters, predoctoral and postdoctoral levels received instructions and assignments from both institutions, based on assessment of self-defined learning goals, educational interests, and relevant experience. The UZ Department of Pharmacy and Pharmaceutical Sciences was represented by a designated professor who alternated between Zimbabwe and the USA to teach and share knowledge as needed. In addition to exchange visits, web based seminars between UZ and UB faculty and scholars were conducted via monthly virtual lecture hall presentations.

Fig. 1
figure 1

Number of student exchanges between UB and UZ from 1998 to 2018. UB: State University of New York at Buffalo; UZ: University of Zimbabwe

Evaluation of successes of the collaboration

The capacity building program was evaluated based on the quantity of new faculty positions, and scientific dissemination was based on the number of abstracts and publications.

Strengthening UZ faculty scholarly capacity and retention of human resources

Leveraging on the MOU, the two institutions successfully competed for three NIH Fogarty International Centre HIV research and training grants (Fig. 2). The first was a two-year supplement request that was linked to the University of California, Berkeley AIDS International Training and Research Program (AITRP) in 2004. This supplement supported two initial scholars and subsequently a five-year AITRP funding was awarded to the UB and UZ to support more scholars. In a parallel AITRP award, three junior faculty members from UZ received masters level training in HIV pharmacology and public health at University of California, Berkeley and University of California, San Francisco.

Fig. 2
figure 2

Timing of HIV Research and Training grants awarded between 1998 and 2018. IAS: International Aids Society; ARV: Antiretroviral; UB: State University of New York at Buffalo; MOU: Memorandum of Understanding; AITRP: Aids Research and Training Program; HRTP: HIV Research and Training Program

In 2009, the UB-UZ collaborative effort renewed its MOU and was awarded a Fogarty AIDS International Training and Research Program (AITRP) grant to implement a pre-doctoral and post-doctoral training initiative with an emphasis on HIV Clinical Pharmacology between UB and UZ. During this period, two doctoral and six Masters of Philosophy students completed their studies. Further, five post-doctoral students and six PharmD students from UB were mentored in Global HIV at UZ (Fig. 3).

Fig. 3
figure 3

Number Graduate Fellows trained between UB and UZ from 1998–2018 by fellowship type. PharmD: Doctor of Pharmacy; MPhil: Master of Philosophy, DPhil: Doctor of Philosophy

The current HIV Research and Training Program (HRTP) grant was awarded in April 2016. Its main thrust is the development and advancement of HIV Clinical Pharmacology training at the pre-doctoral and post-doctoral levels. Four post-doctoral scholars are currently enrolled from behavioural sciences, nanomedicine, paediatrics, genomics, and oncology with the intention of culturing the prospects of a centre for integrated global biomedical sciences. Studies in nanomedicine have been conducted by a single fellow whose focus was on combination therapies for antiretroviral and anti-tuberculosis formulations. The oncology fellow is assessing outcomes in HIV-1 infected patients with advanced cervical cancer undergoing chemoradiation. The behavioural health fellow’s research focuses on the contribution of mental, neurological conditions and psychosocial factors to treatment outcomes and deaths in HIV-infected adolescents. In addition, three scholars, psychiatrists by profession have recently been accepted to the HIV-Alzheimer’s Disease program and will complete mentored research training at UB Alzheimer’s Disease and Memory Disorders Center and focus on HIV related dementias.

The opportunity for UZ scholars to travel abroad and observe faculty in high income countries increased interest in an academic career. Scholars were attached to activities which included rotation through an international specialty laboratory, attachment to Roswell Park Cancer Institute, rotation through immunodeficiency services and translational research training. Four of the scholars joined the School of Pharmacy following research training at UB thus improving staff complement. In addition, progressive levels of training tailored to each fellow’s career development vision were offered, leading to greater career satisfaction and retention of qualified staff with research expertise in the School.

Of note, the program removed barriers to the introduction of nanotechnology research in Zimbabwe. Several successful nanoparticle fabrication projects were conducted, resulting in three publications in peer reviewed journals [11,12,13]. Since the inception of the program, there have been twenty publications, twenty-one poster presentations, and two special journal publications (Table 2).

Table 2 Scholarly outputs by UB-UZ fellows between 1998 and 2018

Technology and skills transfer to support research and practice

In addition to training, the two UB-UZ training programs supported research on assessment of antiretroviral pharmacokinetics to inform optimization of cART therapy in Zimbabwe. In this regard, biomedical scientists from UB led the establishment of an international pharmacology speciality laboratory at UZ (IPSL) [14]. UB on behalf of UZ, solicited equipment from private manufacturers and donors in the US. In 2007, Waters Corporation (Milford, MA) donated a High-Performance Liquid Chromatography instrument. Another donation of an Acquity TQD Liquid chromatograph mass spectrometer was made in 2018 by Waters Corporation to expand the range of assays available in the pharmacology laboratory.

During the laboratory’s developmental period (2009–2012), AITRP scholars were trained in bioanalytical method development, validation and pharmacology aspects applicable in protocol design. Training focused on the development of chromatographic methods, laboratory quality management systems (QMS) and Clinical Pharmacology research and most was done at the Translational Pharmacology Research Core (TPRC) at UB, Buffalo, New York, United States. Additional technical training was done in-house through the NIH Division of AIDS, Clinical Pharmacology Quality Assurance (CPQA) programme after the laboratory was named to participate in this quality assurance programme in 2010 [15]. Consequently, the laboratory implemented required operational systems and methods meeting the CPQA bioanalytical method validation requirements to provide drug assay services for ACTG research protocols.

A milestone was realized in 2014 when the NIH AIDS Clinical Trials Group (ACTG) transitioned the UZ pharmacology laboratory from a developmental designation to a fully supported UZ IPSL for network research. The ACTG supports the largest network of expert clinical and translational investigators and therapeutic clinical trials units and has sites in LMIC countries including Zimbabwe.

Strengthening the HIV clinical pharmacology evidence base for practice and policy

Publications resulting from the post-doctoral fellowship research impacted both policy and practice related to HIV management; in particular, the relevance of concomitant use of herbal medicine despite widespread availability of cART in Zimbabwe. Part of the work was instrumental in the establishment of frameworks for evaluation and implementation of herbal trial protocols and approval of herbal products for sale to the public [16, 17]. Chromatographic assays for antiretroviral drug quantitation were validated in the context of concomitant herbal medicine use. This contributed to capacity building for therapeutic drug monitoring of cART in a high herbal medicine use setting which will be valuable for both practice and research [18]. In addition, other publications highlighted potential and actual adverse drug events which may lead to poor adherence and the need for pharmacovigilance programs to expand to include herbal medicines [19, 20].

In Zimbabwe, the majority of PLHIV receive care and treatment through the national roll-out program that is run by the Ministry of Health and Child Care. Guidance for the treatment of patients is inscribed in the “Guidelines for ART for the prevention and treatment of HIV in Zimbabwe” [21]. Two fellows who graduated from the training program were invited to be part of the adaptation subcommittee for the guidelines. These fellows were invited on the basis of their specialty training/knowledge in HIV pharmacotherapy and their expertise were vital in HIV treatment optimization for the country.

Lessons learnt from challenges

Local partnerships support international collaboration

Recruitment and retention of participants for scholars’ research was a challenge initially. Collaboration with a community-based patient support group was important in building interest in the Fogarty International Center scholars’ research projects. The Perseverance Adherence Respect and Integrity (PARI) support group played a key role in the sensitization, recruitment and retention of study participants for research projects. The Parirenyatwa Hospital outpatient HIV clinic provided space for the PARI support group to meet. Fellows from both UZ and UB gave back to the support group by providing up-to-date health education information and responding to members concerns regarding ART in general. The drug information service resulted in improved medication adherence and patient retention in care [22, 23].

Laboratory facilities were initially provided by UZ to establish the International Pharmacology Speciality Laboratory. However, with the addition of two High Pressure Liquid Chromatography systems, the space became inadequate. An agreement was made in 2012 with the national drug regulatory authority, Medicines Control Authority of Zimbabwe (MCAZ), to house the laboratory at their premises. Cognisant of its limitations, the Government of Zimbabwe has in recent years advocated for public private partnership paradigm shift. Collaborations between private and public institutions to address some of these challenges have yielded positive results [24].

Initially, fellows movement had been planned in one direction, i.e., south to north. As the global health agenda developed, the HRTP appealed to UB students interested in contributing to LMIC global health programs. The local practice context and networks established by HRTP were valuable in supporting training of international Global Health HIV scholars.

Retention of fellows, mentors and support staff

Despite initial efforts to establish strategies for fellow and faculty retention, the country’s unstable economic environment threatened continuity of the program. Both the local private sector or other countries offered better financial security for fellows, mentors and support staff. In order to avoid reversing gains, subsequent grants offered competitive stipends, honoraria and salary thereby ensuring continuity. This proved to be a retention strategy not only for UZ but also for the national HIV program and the MCAZ where several of the fellows also held important posts as expert support.

While this collaboration has been critical in establishing a framework for building capacity in treatment, training and research programmes, it has also led to the retention and development of a critical mass of technically competent researchers who are capable of advancing the research agenda at international level. This was an important lesson learnt when implementing the research and training program through collaborative efforts. Fellows and scholars in the program were able to access resources, mentorship and facilities from high income countries. Consequently this led to a significant decrease in the exodus of scientists to other countries in search of better resources.

Through collaborative agreements, low resource settings are in a position to gain through technology and instrumentation transfer. Whilst the collaboration was originally set up as a training and research program, technology transfer ensued due to the existence of the framework. Finally and more importantly, mentorship in the program has led to the development of a mentorship culture within the local setting. Fellows who have gone through the program become mentors as well to other scientists in training. Consequently, the benefits of the collaboration have yielded positive results beyond those trained in the program.

Conclusions and future plans

Despite the economic challenges, consistent collaboration between the UZ and UB contributed to strengthening UZ faculty scholarly capacity, retention of HIV workforce in Zimbabwe and building the HIV Clinical Pharmacology evidence base. Through the training program, fellows have occupied strategic positions providing technical expertise and influencing policy resulting in optimization of HIV treatment. Capacity building programs in Zimbabwe that use HIV research training to establish a foundation have now led to additional focus areas in cancer and neuropsychology that also contribute to the team science approach. Since its inception, the training program has been consistent, persistent and continues to scale upwards. In the next cycle, the program aims to generate Centres of Excellence in Pharmaceutical Innovation on a regional scale to drive advanced pharmaceutical inventions and innovation across Africa and the world at large.

Availability of data and materials

All data and materials related to this manuscript are available for review by request to the corresponding author.



African/Asian Regional Capacity Development


AIDS Clinical Trials Group


AIDS International Training and Research Program


Clinical Pharmacology Quality Assurance


Combination ART


HIV Research and Training Program


Human Immunodeficiency Virus


International AIDS Society


International pharmacology speciality laboratory


International Pharmacotherapy Education and Research Initiative


Low to Middle Income Countries


Medicines Control Authority of Zimbabwe


Memorandum of understanding


Perseverance Adherence Respect and Integrity


Quality management systems


Translational Pharmacology Research Core


University at Buffalo, State University of New York


University of Zimbabwe


  1. Barré-Sinoussi F. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013;11:877–83.

    Article  Google Scholar 

  2. Maponga CC, Ma Q, Slish JC, Morse GD. HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top Antivir Med. 2007;5:104–10.

    Google Scholar 

  3. Atkins A, Marsden S, Diwan V, Zwarenstein M, ARCADE consortium. North–south collaboration and capacity development in global health research in low- and middle-income countries—the ARCADE projects. Glob Health Action 2016;

    Article  PubMed  PubMed Central  Google Scholar 

  4. World Health Organization. Taking stock: Health worker shortages and the response to AIDS. Strength Health Serv Fight HIV/AIDS. 2006;5:8–10.

  5. World Health Organisation. Zimbabwe Summary Country Profile For HIV/AIDS Treatment Scale-Up December 2005.

  6. Duri K, Stray-Pedersen B, Muller F. HIV/AIDS: The Zimbabwean situation and trends. Am J Clin Med Res. 2013;1(1):15–22.

    Article  Google Scholar 

  7. O’Brien S, Broom A. The rise and fall of HIV prevalence in Zimbabwe: the social, political and economic context. Afri J AIDS Res. 2011;10(3):281–90.

    Article  Google Scholar 

  8. Chikanda A. Skilled health professionals’ migration and its impact on health delivery in Zimbabwe. J Eth Mig Stud. 2006;32(04):667–80.

    Article  Google Scholar 

  9. Noguera M, Alt D, Hirschhorn L, et al. Zimbabwe: Antiretroviral Therapy Program - Issues and Opportunities for Initiation and Expansion. DELIVER/John Snow, Inc., for the U.S. Agency for International Development 2003;19.

  10. World Health Organization. Summary country profile for HIV/AIDS scale-up. Situational analysis 2005;1–2.

  11. Dube A, Reynolds JL, Law WC, et al. Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases. Nanomedicine. 2014;10:831–8.

    Article  CAS  Google Scholar 

  12. Kutscher H, Makita F, DiTursi S, et al. Macrophage targeted nanoparticles for antiretroviral (ARV) delivery. J Pers Nanomed. 2015;1:40–8.

    PubMed  PubMed Central  Google Scholar 

  13. Makita-Chingombe F, Kutscher HL, DiTursi SL. Poly (Lactic-Co-Glycolic) Acid-Chitosan dual loaded nanoparticles for antiretroviral nanoformulations. J Drug Deliv. 2016;2016:3810175.

    Article  Google Scholar 

  14. Mtisi TJ, Maponga CC, Monera-Penduka TG, et al. Strategic establishment of an International Pharmacology Specialty Laboratory in a resource-limited setting. Afr J Lab Med. 2018;7:659.

    Article  Google Scholar 

  15. Difrancesco R, Tooley K, Rosenkranz SL, et al. Clinical Pharmacology quality assurance for HIV and related Infectious diseases research. Clin Pharmacol Ther. 2013;93:479–82.

    Article  CAS  Google Scholar 

  16. Monera-Penduka TG, Jani Z, Maponga CC, et al. Quality and labeling information of Moringa oleifera products marketed for HIV-infected people in Zimbabwe. Public Health Afr. 2016;7:84–8.

    Google Scholar 

  17. Monera-Penduka TG, Maponga CC, Morse GD, Nhachi FB. Capacity for ethical and regulatory review of herbal trials in developing countries: a case study of Moringa oleifera research in HIV-infected patients. J Pharm Policy Pract. 2017;10:9.

    Article  Google Scholar 

  18. Makita-Chingombe F, Ocque AJ, DiFrancesco R, et al. Development and validation of a high-performance liquid chromatography method to determine nevirapine in plasma in a resource-limited setting. Afr J Lab Med. 2019;8:a880.

    Article  CAS  Google Scholar 

  19. Monera-Penduka TG, Maponga CC, Wolfe AR, et al. Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Res Ther. 2017;14:12.

    Article  Google Scholar 

  20. Bepe N, Madanhi N, Mudzviti T, et al. The impact of herbal remedies on adverse effects and quality of life in HIV-infected individuals on antiretroviral therapy. J Infect Dev Ctries. 2011;5:48–53.

    Article  Google Scholar 

  21. Ministry of Health and Child Care, Government of Zimbabwe. National Medicine and Therapeutics Policy Advisory Committee. Guidelines for Antiretroviral Therapy for the Prevention of HIV in Zimbabwe.2016.

  22. Monera TG, Maponga CC. Prevalence and patterns of Moringa oleifera use among HIV positive patients in Zimbabwe: a cross-sectional survey. Public Health Afr. 2012;3:e6.

    Article  Google Scholar 

  23. Mudzviti T, Maponga CC, Khoza S, et al. The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in Zimbabwe. AIDS Res Treat. 2012;2012:434171.

    PubMed  PubMed Central  Google Scholar 

  24. Zimbabwe Ministry of Health. Extended Zimbabwe National HIV and AIDS Strategic Plan 2015;42–6.

Download references


The authors would like to thank the following IPERI team and other collaborators for their unwavering support to this project: Dexter Chagwena, Noleen Masikati, Tinashe Mwayera, Martin Zende and Primrose Jaravani.


One of the fellows was supported in part by an International Supplement to grant number R01DA015024-03S2 from the National Institute of Drug Abuse. The project described was supported in part by grant numbers D43TW010313, D43TW007991 and D43TW007991 01A2S1 from the Fogarty International Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center or the National Institutes of Health. The project described was supported in part by a subaward SA5335-32119 (2006–2008) to the University at Buffalo from University of California, Berkeley grant number D43TW000003 from the Fogarty International Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center or the National Institutes of Health. This publication was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This project has been funded in part by a subaward to the University at Buffalo in support of a Pharmacology Specialty Laboratory and to the University of Zimbabwe in support of a developmental International Pharmacology Specialty Laboratory under Award Numbers UM1 AI068634, UM1 AI068636 and UM1 AI106701 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Center for AIDS Research (CFAR): This publication was made possible in part through core services and support from the University of Rochester Center for AIDS Research (CFAR), an NIH-funded program (P30AI078498). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Clinical Pharmacology Quality Assurance Program: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract numbers HHSN272201500006C and HHSN272200800019C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations



CCM conceived the idea for the manuscript. CCM and TGM structured and drafted the manuscript. All authors contributed to the collation and analysis of the data, critical revision of the manuscript and approval of the final version. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Tsitsi G. Monera-Penduka.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Maponga, C.C., Monera-Penduka, T.G., Mtisi, T.J. et al. Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting. Cost Eff Resour Alloc 19, 73 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • HIV
  • Research
  • Capacity building
  • Clinical pharmacology
  • Collaboration
  • Resource-limited